Publicité
La bourse ferme dans 48 min

  • CAC 40

    7 575,18
    -33,97 (-0,45 %)
     

  • Euro Stoxx 50

    4 924,60
    +8,66 (+0,18 %)
     

  • Dow Jones

    39 239,05
    +111,25 (+0,28 %)
     

  • EUR/USD

    1,0719
    +0,0036 (+0,33 %)
     

  • Gold future

    2 335,50
    +22,30 (+0,96 %)
     

  • Bitcoin EUR

    57 872,69
    +387,31 (+0,67 %)
     

  • CMC Crypto 200

    1 295,15
    +29,00 (+2,29 %)
     

  • Pétrole WTI

    81,64
    +0,74 (+0,91 %)
     

  • DAX

    18 241,56
    +86,32 (+0,48 %)
     

  • FTSE 100

    8 213,60
    -11,73 (-0,14 %)
     

  • Nasdaq

    17 854,97
    +49,82 (+0,28 %)
     

  • S&P 500

    5 486,63
    +8,73 (+0,16 %)
     

  • Nikkei 225

    39 341,54
    -325,53 (-0,82 %)
     

  • HANG SENG

    17 716,47
    -373,46 (-2,06 %)
     

  • GBP/USD

    1,2660
    +0,0036 (+0,28 %)
     

Biovica Appoints Anders Morén as CFO

Biovica International

UPPSALA, SWEDEN / ACCESSWIRE / October 20, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, today announces that Anders Morén has been appointed as the company's Chief Financial Officer (CFO). Anders Morén will begin his new position on January 1, 2023.

Most recently, Anders Morén comes from the global pharmaceutical company Gilead where he was responsible for the finance function for a large part of Europe, Middle East and Africa (EMEA, with over SEK 10 billion in annual sales).

"I am very happy to welcome Anders Morén to Biovica. Among other things, he has participated in several successful launches at Gilead, experiences that will be very valuable to us when we launch DiviTum®TKa on the American market. I am very proud of the strong team Biovica has built and am humbled by the competent people we have managed to attract," said Anders Rylander, CEO of Biovica.

"I am very much looking forward to being part of the exciting journey that Biovica is facing. Based on my many years in the pharmaceutical industry, I hope to be able to contribute to the continued development of the company. The goal is to switch up and manage various opportunities to create future value, both for patients and shareholders," said Anders Morén, the next CFO of Biovica.

PUBLICITÉ

Anders Morén succeeds Cecilia Driving, who, as previously announced, is leaving Biovica on December 31, 2022.

Contact

Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com

Biovica - Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information please visit: www.biovica.com.

Attachments

Biovica appoints Anders Morén as CFO

SOURCE: Biovica International



View source version on accesswire.com:
https://www.accesswire.com/721296/Biovica-Appoints-Anders-Morn-as-CFO